|
|
||||||||
INSERM U317, Institut Louis Bugnard, Université Paul Sabatier, CHU Rangueil, Batiment L3, 31403, Toulouse cedex 04, France
1 To whom correspondence should be addressed. e-mail: saulnier{at}rangueil.inserm.fr
| ABSTRACT |
|---|
|
|
|---|
In conclusion, our results reveal the existence of a secreted lyso-PLD activity regulated during adipocyte-differentiation and involved in extra cellular production of synthesis of LPA by adipocytes.
Abbreviations: CHCl3, chloroform; CM, conditioned medium; LPA, lysophosphatidic acid; LPAAT, lysophosphatidic acid acyltransferase; LPAF, lyso-platelet activated factor; LPA-SA, lysophosphatidic acid-synthesizing activity; LPC, lysophosphatidylcholine; LPG, lysophosphatidylglycerol; MeOH, methanol; PA, phosphatidic acid; PC, phosphatidylcholine; PLA2, phospholipase A2; PLD, phospholipase D
Supplementary key words adipose tissue 3T3F442A preadipocytes human mouse phospholipase D phospholipase A2 conditioned medium culture lysophospholipids lysophosphatidylcholine phosphatidic acid radioenzymatic assay
| INTRODUCTION |
|---|
|
|
|---|
Two major pathways of LPA synthesis have been described: i) phospholipase A2-dependent deacylation of phosphatidic acid (35); and ii) lysophospholipase D (lyso-PLD) dependent hydrolysis of other lysophospholipids such as lysophosphatidylcholine (68). The precise contribution of these pathways in cellular production of LPA is still a matter of debate.
LPA is found in abundance in serum (bound to albumin) (912) resulting from platelet aggregation (10, 13). However, LPA is also found in other biological fluids such as plasma of patients with ovarian cancer (14), ascites (15), aqueous humor (16), follicular fluids (8), and extracellular fluid of adipose tissue (17). This suggests the involvement of other cell types in LPA production. LPA can indeed be produced by cancer cells (18) and adipocytes (17).
The initial aim of the present study was to depict the metabolic pathways involved in extracellular production of LPA by adipocytes. We found that, in parallel to LPA, adipocytes secrete a soluble lyso-PLD catalyzing hydrolysis of lysophosphatidylcholine into LPA.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Human adipose tissue was obtained from healthy, drug free women undergoing abdominal dermolipectomy for plastic surgery according to the regulation of the Ethical Committee of Faculty Hospital. Adipose tissue was carefully dissected out from blood vessels and cut in small pieces (average weight 20 mg) as previously described (20). Before utilization adipose tissue explants were washed twice in sterile PBS.
In order to study extra-cellular production of LPA, 3T3F442A adipocytes (3 cm diameter plate) or human adipose tissue explants (0.7 g) were incubated in 1 ml of sterile HEPES-buffer (HB) (118 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 12.4 mM HEPES, 6 mM glucose, pH 7.4) supplemented with 1% fatty acid-free BSA (HB-BSA). Incubations were performed at 37°C in an humidified atmosphere containing 7% CO2. At different time point (0 to 48 h), incubation medium was collected, centrifuged for 15 min at 800 g to eliminate detached cells and cell debris, and frozen at -20°C before LPA quantification. The collected incubation media were called conditioned media (CM). LPA quantification was performed either directly after defrosting (initial) or after further incubation of the defrosted sample at 37°C for various period of time in sterile condition.
Quantification of LPA
Quantification of LPA was performed using a radioenzymatic assay as previously described (21). Phospholipids were extracted from CM with 1 vol of 1-butanol followed by evaporation of the solvent under nitrogen. Dry phospholipids were resuspended in 200 µl of reaction medium (1 µl [14C]oleoyl CoA (RAS 55 mCi/mmole, NEN), 20 µl Tris (pH 7.5) 200 mM, 10 µl of semi-purified lysophosphatidic acid acyl transferase (LPAAT), 8 µl of sodium orthovanadate 500 µM, and 161 µl H2O (containing 1 mg/ml Tween 20), and incubated for 120 min at 20°C. The mixture was vortexed every 15 min. The reaction was stopped by addition of 400 µl of CHCl3/MeOH/HCl 12 N (1/1/0.26) followed by a vigorous shaking and by 10 min centrifugation at 3,000 g. The lower CHCl3 phase was evaporated under nitrogen, resuspended in 20 µl of CHCl3/MeOH (1/1), spotted on a silica gel 60 TLC glass plate (Merck), and separated using CHCl3/MeOH/NH4OH/ H2O (65/25/0.9/3) as a solvent. The plate was autoradiographed overnight to localize the [14C]phosphatidic acid spots, which were then scrapped and counted with 3 ml of scintillation cocktail.
Phospholipids
Palmitoyl-, stearoyl-, oleoyl-lysophosphatidylcholine palmitoyl-lyso-platelet activating factor, and dioleoyl-phosphatidic acid were from Sigma. Oleoyl-lysophosphatidylglycerol was from Avanti Polar Lipids. Linoleoyl-lysophosphatidylcholine was obtained by treatment of dilinoleoyl-phosphatidylcholine (Avanti Polar Lipids) with pancreatic phospholipase A2 (Sigma) followed by separation and extraction on TLC. Arachidonoyl-lysophosphatidylcholine was obtained by treatment of palmitoyl-arachidonoyl-phosphatidylcholine (Sigma) with type XI lipase from Rhizopus arrhizus (Sigma) followed by separation and extraction on TLC. All phospholipids were solubilized in methanol, evaporated under nitrogen, and resuspended in HB-BSA. The final concentration was verified by using phosphorus measurement (22).
| RESULTS |
|---|
|
|
|---|
|
|
|
In order to determine whether LPA-SA was soluble or associated with cell particules (membranes, vesicules), CM was subjected to ultra-centrifugation (100,000 g, 60 min, 4°C). The totality of LPA-SA remained in a supernatant after ultracentrifugation (not shown), strongly suggesting that LPA-SA was a soluble enzyme-activity. Above results suggested that LPA-SA was resulting from a soluble enzyme-activity secreted or released by adipocytes.
LPA-SA requires divalent cations
In order to better characterize LPA-SA, the influence of ion chelators and divalent ions was tested. EDTA and phenanthroline both inhibited LPA-SA present in 3T3F442A adipocyte incubation medium, with IC50 of 0.02 and 0.09 mM respectively (Fig. 4A, B)
. The inhibitory effect of 0.05 mM EDTA was completely reversed by 5 mM CoCl2, partially reverted by 5 mM CaCl2, and not affected by 5 mM MgCl2 (Fig. 5)
. These results showed that LPA-SA required divalent-ions, with a preference for Co++ ions. Similar metal ion preference was described for a lyso-PLD catalyzing hydrolysis of lysophospholipids into LPA in rat plasma (6, 23). This resemblance suggested that LPA-SA could correspond to a lyso-PLD.
|
|
Among lysophospholipids, lysophosphatidylcholine is usually the most abundant. Phospholipids co-migrating with LPC were purified from 1 ml adipocyte CM by preparative TLC, solubilized in 1 ml HB-BSA, and treated with bacterial PLD before quantification of LPA. This led to a concentration of LPA of 323 ± 12 nM LPA (n = 3). This concentration was very close to what was obtained after treatment of whole CM with bacterial PLD: 299 ± 25 nM.
Above results showed that, in addition to LPA, adipocyte CM also contained other lysophospholipids (mainly lysophosphatidylcholine) constituting potential substrates for a lyso-PLD. Results also showed that adipocyte CM did not contain detectable PLA2-sensitive LPA precursors, therefore excluding that LPA-SA could be a PLA2.
LPA-SA behaves like a lysophospholipase D
If LPA-SA was a lyso-PLD, addition of exogenous lysophospholipids in adipocyte CM should increase LPA concentration in CM. As shown in Fig. 6
, addition of exogenous (2 µM final concentration) oleoyl-LPC, oleoyl-LPG, or palmitoyl-LPAF significantly increased the amount of LPA generated by 6 h incubation at 37°C of adipocyte CM. Conversely, no increase was observed by addition of exogenous dioleoyl-PA (Fig. 6). In parallel, no LPA was detected when LPC, LPG, or LPAF were incubated for 6 h at 37°C in HB-BSA alone (not shown). Above results showed that adipocyte CM contained a lyso-PLD, and did not contain detectable PLA2 activity.
|
In order to determine the substrate specificity of adipocyte lyso-PLD, different LPC species were added in adipocyte CM (2 µM final concentration) and the amount of LPA generated after 6 h incubation was determined. The rate of conversion of palmitoyl-LPC, stearoyl-LPC, oleoyl-LPC, linoleoyl-LPC, and arachidonoyl-LPC into LPA were 6.3 ± 0.7%, 2.9 ± 0.2%, 4.9 ± 0.5%, 5.2 ± 0.3%, and 4.0 ± 0.7% (n = 3), respectively. These data revealed that, except for stearoyl-LPC, which exhibited a slightly lower conversion, the other LPC substrates exhibited equivalent conversion into LPA, suggesting that adipocyte lyso-PLD did not exhibit substantial substrate specificity.
Adipocyte lyso-PLD-activity does not result from a classical PLD
Some phospholipase D such as the PLD1 and PLD2 are characterized by their ability to catalyze, in the presence of primary alcohol, a transphosphatidylation reaction producing phosphatidylacohol instead of phosphatidic acid (24). If adipocyte lyso-PLD activity was due to the action of PLD1 or PLD2, it should be blocked by primary alcohols. As shown in Fig. 7
, ethanol (from 0.5% to 10%) did not inhibit, but rather increased (at 5% and 10%) adipocyte LPA-SA. Similar increase was observed with 0.5% and 1% 1-butanol (Fig. 7). Above results showed that PLD1 or PLD2 could not be responsible for adipocyte LPA-SA.
|
2-adrenergic receptors (17). We found that
2-adrenergic receptor stimulation did not influence lyso-PLD secretion nor production of lyso-PC by adipocytes (not shown), showing that
2-adrenergic-dependent regulation of extra-cellular production of LPA is likely mediated by another pathway which remains to be clarified. In order to determine the existence of possible regulations of adipocyte lyso-PLD, its activity was measured during the course of adipocyte differentiation. For that purpose, confluent 3T3F442A undifferentiated preadipocytes were grown in a standardized differentiating medium (see Materials and Methods). Based upon analysis of specific markers (expression of the adipocyte-lipid binding protein mRNA, accumulation of triglycerides), adipocyte differentiation occurs between 2 and 5 days after confluence (25). Confluent preadipocytes and adipocytes (day 7 after confluence) were incubated in HB-BSA for 7 h. LPA present in the conditioned medium was quantified either directly (this corresponded to the basal extra-cellular production of LPA by the cells), or after 6 h further incubation at 37°C (this corresponds to the secretion of lyso-PLD), or after 45 min further incubation at 37°C in the presence of bacterial PLD (this corresponded to the production of LPC). Preadipocytes produced significantly less LPA (3.6-fold) and less lyso-PLD activity (6-fold) than adipocytes (Table 1). In parallel, no major alteration in lyso-PC production was observed between preadipocytes and adipocytes (Table 1). These results suggested the existence of a differentiation-dependent regulation of lyso-PLD activity that could account for a differentiation-dependent regulation of extra-cellular production of LPA.
|
| DISCUSSION |
|---|
|
|
|---|
In the present study we demonstrate that, in parallel to LPA, adipocyte is also able to secrete a LPA-synthesizing activity (LPA-SA). Biochemical analysis strongly suggests that LPA-SA corresponds to a soluble lyso-PLD catalyzing transformation of LPC into LPA.
The hypothesis that LPA-SA could indeed correspond to a lyso-PLD is supported by several observations. First, LPA-SA exhibits similar sensitivity to the the ion-chelators (EDTA and phenanthrolin) and similar sensitivity to cobalt ion, than a lyso-PLD activity previously described in rat plasma (23). Second, adipocyte CM is able to transform exogenously added lysophospholipids into LPA, a reaction that can only be achieved by a lyso-PLD. Based on our results it appeared that the main substrate of adipocyte lyso-PLD is LPC since it is the main PLD-transformable LPA-precursor (mainly PLC) present in adipocyte CM. By using various exogenous lysophospholipids, we also found that LPC appears as the best substrate of adipocyte lyso-PLD as compared with LPG and LPAF. In addition, by using various LPC species we found that adipocyte lyso-PC does not exhibit substantial substrate specificity regarding the nature of the fatty acid composing its substrate. In that respect, adipocyte lyso-PLD appears to be different from the lyso-PLD previously described in rat plasma and which was demonstrated to hydrolyze polyunsaturated-LPC preferentially to the saturated-LPCs (6, 26).
In platelets and ovarian cancer cells, LPA synthesis has been proposed to result from deacylation of phosphatidic acid by a phospholipase A2-activity (3, 5, 18). In adipocyte CM, we could not detect any transformation of phosphatidic acid into LPA, showing that phospholipase A2-activity could not account for LPA-SA. In addition, treatment of adipocyte CM with pancreatic phospholipase A2 did not increase LPA concentration, suggesting that PA was undetectable in adipocyte CM. Therefore, the direct involvement of phospholipase A2 in LPA-SA could reasonably be excluded. Nevertheless, phospholipase A2 very likely plays an indirect role by providing the substrate of the lyso-PLD, lysophosphatidylcholine, resulting from hydrolysis of phosphatidylcholine.
Because of its relatively high polarity, it is unlikely that LPA could easily diffuse through phospholipid membranes. Therefore, when present extra-cellularly, LPA would result from secreted or ectopic enzyme(s), rather than from intracellular enzyme(s). This hypothesis is in agreement with previous report showing that exogenous bacterial PLD exhibiting lyso-PLD activity can produce LPA in the outer membrane leaflet of intact cells (7). The fact that adipocyte lyso-PLD was found in CM after separation from the cells suggests that this enzyme could be secreted or released from adipocytes. This hypothesis is reinforced by the fact that adipocyte lyso-PLD activity was found to be soluble and not associated with a particulate fraction.
Although the precise mechanisms of its secretion/release remain to be established, adipocyte lyso-PLD is, to our knowledge, the first extracellular lyso-PLD of known cellular origin in mammals. Tokomura et al. have reported the existence of a lyso-PLD activity in rat plasma (6) as well as in human follicular fluids (8). Whereas the involvement of this lyso-PLD activity in LPA production has been demonstrated, the structure of the enzyme, as well as its cellular origin, remains completely unknown. Therefore, the discovery of an adipocyte lyso-PLD activity gives a unique opportunity to purify and clone the enzyme. Interestingly, our data show that lyso-PLD activity is up-regulated during adipocyte differentiation. It is therefore likely that the adipocyte lyso-PLD gene belongs to a set of genes positively regulated during adipocyte differentiation, and this could help for its identification.
As we previously showed, LPA produced by adipocytes is able to activate the growth of the adipocyte precursors (preadipocytes) (17), one of the key events of adipose tissue development (adipogenesis). Preadipocytes being located in the close vicinity of adipocytes in the adipose tissue, adipocyte production of LPA could play an important role in paracrine control of adipose tissue development. In order to control this paracrine function of LPA, it is required either to target LPA-receptors (EDG-2 receptors) present in preadipocytes (25), or to act on adipocyte-LPA synthesis. Consequently, adipocyte lyso-PLD could represent an interesting target to control adipose tissue development.
| ACKNOWLEDGMENTS |
|---|
Manuscript received October 2, 2001 and in revised form February 22, 2002.
| REFERENCES |
|---|
|
|
|---|
2A-adrenergic receptor expression in 3T3F442A preadipocytes and adipocytes. Biochem. Biophys. Res. Commun. 235: 765773.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
X. Ye Lysophospholipid signaling in the function and pathology of the reproductive system Hum. Reprod. Update, June 25, 2008; (2008) dmn023v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Giganti, M. Rodriguez, B. Fould, N. Moulharat, F. Coge, P. Chomarat, J.-P. Galizzi, P. Valet, J.-S. Saulnier-Blache, J. A. Boutin, et al. Murine and Human Autotaxin {alpha}, {beta}, and {gamma} Isoforms: GENE ORGANIZATION, TISSUE DISTRIBUTION, AND BIOCHEMICAL CHARACTERIZATION J. Biol. Chem., March 21, 2008; 283(12): 7776 - 7789. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Chan, W. Peters, Y. Xu, J. Chun, R. V. Farese Jr, and S. Cases LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA) J. Leukoc. Biol., November 1, 2007; 82(5): 1193 - 1200. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Panupinthu, L. Zhao, F. Possmayer, H. Z. Ke, S. M. Sims, and S. J. Dixon P2X7 Nucleotide Receptors Mediate Blebbing in Osteoblasts through a Pathway Involving Lysophosphatidic Acid J. Biol. Chem., February 2, 2007; 282(5): 3403 - 3412. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. Simon, D. Daviaud, J. P. Pradere, S. Gres, C. Guigne, M. Wabitsch, J. Chun, P. Valet, and J. S. Saulnier-Blache Lysophosphatidic Acid Inhibits Adipocyte Differentiation via Lysophosphatidic Acid 1 Receptor-dependent Down-regulation of Peroxisome Proliferator-activated Receptor {gamma}2 J. Biol. Chem., April 15, 2005; 280(15): 14656 - 14662. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ferry, E. Tellier, A. Try, S. Gres, I. Naime, M. F. Simon, M. Rodriguez, J. Boucher, I. Tack, S. Gesta, et al. Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation. UP-REGULATED EXPRESSION WITH ADIPOCYTE DIFFERENTIATION AND OBESITY J. Biol. Chem., May 9, 2003; 278(20): 18162 - 18169. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |